Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.

Fioretti F, Butler J, Udell JA, Schuyler Jones W, Petrie MC, Harrington J, Mattheus M, Bauersachs J, Bayes-Genis A, Goodman SG, Gasior T, Januzzi JL, Lopes RD, Ponikowski P, Rossello X, Schou M, van der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF, Anker SD

Open source

DOI: 10.1002/ehf2.15393
Published: 2025 Dec
Container: ESC heart failure
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ehf2.15393,
  title = {Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.},
  author = {Fioretti F and Butler J and Udell JA and Schuyler Jones W and Petrie MC and Harrington J and Mattheus M and Bauersachs J and Bayes-Genis A and Goodman SG and Gasior T and Januzzi JL and Lopes RD and Ponikowski P and Rossello X and Schou M and van der Meer P and Vinereanu D and Zieroth S and Brueckmann M and Sumin M and Bhatt DL and Hernandez AF and Anker SD},
  year = {2025},
  journal = {ESC heart failure},
  doi = {10.1002/ehf2.15393},
  url = {https://doi.org/10.1002/ehf2.15393}
}

RIS

TY  - JOUR
TI  - Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.
AU  - Fioretti F
AU  - Butler J
AU  - Udell JA
AU  - Schuyler Jones W
AU  - Petrie MC
AU  - Harrington J
AU  - Mattheus M
AU  - Bauersachs J
AU  - Bayes-Genis A
AU  - Goodman SG
AU  - Gasior T
AU  - Januzzi JL
AU  - Lopes RD
AU  - Ponikowski P
AU  - Rossello X
AU  - Schou M
AU  - van der Meer P
AU  - Vinereanu D
AU  - Zieroth S
AU  - Brueckmann M
AU  - Sumin M
AU  - Bhatt DL
AU  - Hernandez AF
AU  - Anker SD
PY  - 2025
JO  - ESC heart failure
DO  - 10.1002/ehf2.15393
UR  - https://doi.org/10.1002/ehf2.15393
ER  -

APA

F, F., J, B., JA, U., W, S. J., MC, P., J, H., M, M., J, B., A, B., SG, G., T, G., JL, J., RD, L., P, P., X, R., M, S., P, V. D. M., D, V., S, Z., M, B., M, S., DL, B., AF, H., & SD, A. (2025). Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.. ESC heart failure. https://doi.org/10.1002/ehf2.15393

Source records

pubmed · retrieved 2026-09-26T02:50:43.304Z